<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665665</url>
  </required_header>
  <id_info>
    <org_study_id>NN9112-1846</org_study_id>
    <nct_id>NCT00665665</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers</brief_title>
  <official_title>Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be conducted in the United States of America (USA). The aim of the trial is
      to investigate whether the drug is safe, well tolerated and to investigate the efficacy of
      NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and
      placebo. This registration covers the phase 2 part of a combined phase 1/phase 2 trial (phase
      1 part of trial conducted between November 2007 and April 2008).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial is terminated due to re-evaluation of the compound
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of NNC 0070-0002-0182 multiple doses</measure>
    <time_frame>after 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of NNC 0070-0002-0182 and its isomer</measure>
    <time_frame>at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in food consumption and hunger</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight, waist and hip measurements and mood</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition and resting metabolism</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention arm D only: Change in insulin sensitivity (HOMA)</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention arm D only: Change from baseline in body fat (DEXA)</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention arm D only: Change from baseline in indirect calorimetry</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention arm D only: Change from baseline in adiponectin, hsCRP</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention arm D only: Antibody assessment</measure>
    <time_frame>at 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0070-0002-0182</intervention_name>
    <description>4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo for s.c. injection</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0070-0002-0182</intervention_name>
    <description>12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0070-0002-0182</intervention_name>
    <description>32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0070-0002-0182</intervention_name>
    <description>60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 30.0-39.0 kg/m2 (obese)

          -  Females who consent to using double barrier method of contraception, are
             post-menopausal and older than 50 years, or have had total hysterectomy

        Exclusion Criteria:

          -  Clinically significant diseases

          -  Blood pressure greater than 140/90 mmHg

          -  Evidence of depression

          -  Recent diet attempts, treatment with diet drugs (within 3 months)

          -  Liposuction or other surgery for weight loss within the last year

          -  Evidence of eating disorders (bulimia, binge eating)

          -  Restricted diets (Kosher, vegetarian)

          -  Smoker or history of drug or alcohol abuse

          -  Females of childbearing potential: positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

